Christopher Morrow

5PUBLICATIONS
72CO-AUTHORS
Predictive and prognostic markersMolecular targetsWastewater treatment processesCarbon capture engineering (excl. sequestration)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Feb 02, 2026
Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study.

John F R Robertson, Teimuraz Gogitidze, Zaza Katashvili

|Aug 11, 2025
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.

Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego

|May 13, 2024
Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC.

Thomas G Hayhow, Beth Williamson, Mandy Lawson

|Sep 19, 2023
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.

Mandy Lawson, Natalie Cureton, Susana Ros

|Dec 06, 2021
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.

Andi K Cani, Emily M Dolce, Elizabeth P Darga

Pageof 1

Frequent Collaborators

3 joint publications

Justin P O Lindemann

2 joint publications

Alastair Mathewson

2 joint publications

Teresa Klinowska

2 joint publications

David I Fisher